<DOC>
	<DOCNO>NCT02856113</DOCNO>
	<brief_summary>This study evaluate efficacy safety alogliptin 25 mg daily ( QD ) compare placebo administer monotherapy , add onto background metformin alone , insulin alone , combination metformin insulin pediatric participant 10 17 year age type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Phase 3 Alogliptin Pediatric Study</brief_title>
	<detailed_description>The drug test study call alogliptin . Alogliptin test treat child 10 17 year age type 2 diabetes mellitus ( T2DM ) experience inadequate glycemic control . This study look glycosylated hemoglobin ( HbA1c ) fluctuations child take alogliptin addition background antidiabetic therapy . The study enroll approximately 200 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Alogliptin 25 mg - Placebo ( dummy inactive pill ) - tablet look like tablet contain alogliptin 25mg active ingredient ( i.e . alogliptin ) All participant ask take one tablet time day throughout study addition current background antidiabetic therapy ( metformin and/or insulin ) applicable . This multi-center trial conduct worldwide . The overall time participate study approximately 56 week . Participants make multiple visit clinic , contact telephone 2 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Has confirm diagnosis type 2 diabetes mellitus ( T2DM ) use American Diabetes Association ( ADA ) World Health Organization ( WHO ) criterion ( laboratory determination fast plasma glucose ( FPG ) ≥126 mg/dL , random glucose ≥200 mg/dL [ ≥11.10 mmol/L ] , glycosylated hemoglobin ( HbA1c ) ≥6.5 % , 2hour oral glucose tolerance test [ OGTT ] glucose ≥200 mg/dL ) , document participant ' medical record . 2 . Documented fast Cpeptide concentration ≥0.6 ng/mL ( ≥0.20 nmol/L ) ( draw least 1 week treatment ketosis acidosis , applicable ) . 3 . Documented glutamic acid decarboxylase [ GAD ] 65 islet cell antigen [ ICA ] 512 antibody upper limit normal reference range . 4 . Has body mass index ( BMI ) ≥85th percentile , document Screening . 5 . Is think able swallow tablet contain study medication . 6 . The participant and/or his/her legal representative ( ie , parent legal guardian ) able willing monitor blood glucose concentration home glucose monitor complete participant diary . 1 . Has history hypersensitivity allergy alogliptin , dipeptidyl peptidase4 ( DPP4 ) inhibitor , metformin , insulin related compound . 2 . Has confirm diagnosis type 1 diabetes mellitus maturityonset diabetes young ( MODY ) . 3 . Has hemoglobin level &lt; 11.0 g/dL ( &lt; 110 g/L ) males &lt; 10.0 g/dL ( &lt; 100 g/L ) females . 4 . Has history hemoglobinopathy may affect determination HbA1c level . 5 . Has history bariatric surgery . 6 . Has history proliferative diabetic retinopathy within 6 month prior Screening . 7 . Has 1 episode diabetic ketoacidosis ( DKA ) time diagnosis T2DM . 8 . Has history 1 episode pancreatitis . 9 . Has serum creatinine ≥1.5 mg/dL male participant ≥1.4 mg/dL female participant , creatinine clearance &lt; 60 mL/min base calculation central lab use CockcroftGault approximation Screening Visit . 10 . Has document history infection human immunodeficiency virus chronic active viral hepatitis . 11 . The participant and/or his/her legal representative ( ie , parent legal guardian ) unable understand verbal write English , language certify translation approve informed consent/assent available . Additional Criteria That Must Met Prior Randomization : 1 . Must HbA1c level ≥6.5 % &lt; 11.0 % . 2 . Must receive antidiabetic agent metformin insulin within 12 week prior randomization . 3 . Must receive oral parenteral steroid 3 week ( cumulatively ) within 6 month prior randomization receive course oral parenteral steroid within 2 month prior randomization . 4 . Has systolic blood pressure &lt; 160 mmHg diastolic pressure &lt; 100 mmHg . ( Antihypertensive medication allow study ) . 5 . Has alanine aminotransferase ( ALT ) level &lt; 3 × upper limit normal ( ULN ) ALT level &lt; 5 × ULN confirm diagnosis nonalcoholic fatty liver disease ( NAFLD ) . 6 . Does plan leave geographic area within 1 calendar year follow randomization .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>